Navigation Links
Advance in Bowel Cancer Test Research
Date:6/3/2009

SYDNEY, June 3 /PRNewswire/ -- Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls.

Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions.

"If we can now show that the levels of these biomarkers in blood or stool also correlate strongly with disease state in a large group of patients with cancer or pre-cancer lesions (ie adenomatous polyps) we may have the basis for a very important new diagnostic weapon in the fight against bowel cancer," says CSIRO's Preventative Health National Research Flagship Theme Leader in Colorectal Cancer and Gut Health, Dr Trevor Lockett.

According to Professor Graeme Young from Flinders University's Centre for Cancer Prevention and Control, regular screening for bowel cancer in people aged 50 years and over is a powerful tool for reducing the impact of the disease in Australia.

"If we can develop a screening test that can point to the presence of clinically important pre-cancerous adenomas which are then removed during follow-up colonoscopy, we will actually be able to prevent the occurrence of bowel cancer in some cases," Professor Young says.

The CEO of Clinical Genomics Pty Ltd, Lawrence La Pointe, says if a more robust screening test for bowel cancer and especially pre-cancer lesions emerges, the research team will have achieved a major advance likely to further improve screening outcomes and more precisely identify those people most likely to benefit from colonoscopic investigation.

Digestive Diseases
'/>"/>

SOURCE Clinical Genomics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Today DePuy Synthes Companies ... angle plating systems featuring its proprietary variable angle ... screw trajectory to match patient anatomy and fracture ... bone. The systems are being introduced in conjunction ... (AOFAS) and the International Federation of Foot & ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... March 5, 2012   Synteract , Inc., a full-service contract ... MBA, as senior vice president of sales and marketing and ... president, global project management, to support growth in the company ... Barr, COO Stewart Bieler, and CFO Patrik Jeanmonod on the ...
... Checkpoint Surgical has received the CE mark ... intraoperative neuroprotective stimulator that helps surgeons locate, identify ... to facilitate nerve preservation and repair. ... certification demonstrates that a medical device meets rigorous ...
Cached Medicine Technology:Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3Checkpoint Surgical Receives CE Mark 2
(Date:9/21/2014)... PITTSBURGH, PA (PRWEB) September 21, 2014 ... energy boost without having to consume sugary, foul-tasting energy ... also did not always just want to drink plain, ... this alternative energy booster." , He developed ENERG CHEWING ... also assist with weight loss. The formula contains nutritious ...
(Date:9/21/2014)... 2014 "I want to help people ... but haven’t the money for chiropractors," said an inventor ... such a product for myself." , The Stretch is ... the thigh muscles and align the spine properly. It ... discomfort of pinched nerves. Compact and easy to use, ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2
... Ga., April 30 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... and Merrill Lynch 2009 Health Care Conference in New ... webcast. The Company,s presentation is scheduled for Tuesday, ...
... - Clinic operations revenue ... sales revenue increases 173%,VANCOUVER, April 30 /PRNewswire-FirstCall/ - CRH ... of $6,655,342 for the year ended 2008 compared to ... operations revenue increased 100% to $6,047,590 for the year ...
... proven calcium channel blocker, angiotensin receptor blocker and ... In a clinical trial, Exforge HCT demonstrated significantly ... to all dual combinations of its components - ... medications to help control their blood pressure and ...
... /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") ... markets specialty pharmaceutical products in China, today announced ... Company on investor communications best-practices in the U.S. ... China Pharma, stated, "Our decision to hire ICR ...
... added benefit from cholesterol-reducing agent , , , THURSDAY, ... cells to release cholesterol might prove effective in ... new study suggests. , George Washington University researchers ... found that the treatment restored cholesterol outflow from ...
... HealthSouth Corporation (NYSE: HLS ) today announced it ... Conference on May 12-14, 2009, at the Four Seasons Hotel ... Executive Vice President and Chief Financial Officer John Workman will ... (7:55 a.m. CT). The presentation will be webcast live and ...
Cached Medicine News:Health News:CRH Medical reports year end results 2Health News:CRH Medical reports year end results 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7Health News:China Pharma Holdings, Inc. Retains Global Investor Communications Team 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: